Marijuana Users May Be More Likely to Survive Acute Heart Failure Hospitalization Steve Stiles Medscape Medical News © 2019 , September 16, 2019 PHILADELPHIA — There's sunny news, potentially, for patients with heart failure who are keen on cannabis. Hospitalized patients with a primary diagnosis of acute heart failure (HF) who say they are marijuana users are more likely to survive to discharge than nonusers, and they stay fewer days at less cost to the hospital, an observational study suggests. It may be only patients with heart failure and reduced ejection fraction (HFrEF) who benefit, not those with heart failure and preserved ejection fraction (HFpEF), [...]
Lire la suiteCannabis et sécurité routière : en zone rurale, la répression plus dangereuse que la consommation ? Sur les routes de Lozère, une présomption d’innocence en ligne discontinue paru dans lundimatin#195, le 10 juin 2019 https://lundi.am/Cannabis-et-securite-routiere-en-zone-rurale-la-repression-plus-dangereuse-que-la-consommation Un lecteur de lundimatin nous a fait parvenir cette longue enquête à propos de la lutte contre la conduite après avoir fait usage de stupéfiants en Lozère. L’auteur est allé à la rencontre d’habitants et d’élus très critiques quant aux conséquences pratiques des tests salivaires. A cela s’ajoutent de nombreux témoignages de faux positifs et de conducteurs qui finissent sur le bord de la route : une punition vécue comme une injustice [...]
Lire la suiteRenseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique. Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]
Lire la suitePsychedelics as Medicines for Substance Abuse Rehabilitation : Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca Michael Winkelman Current Drug Abuse Reviews, 2014, 7, 101-116 Abstract : Substances known as psychedelics, hallucinogens and entheogens have been employed in ethnomedical traditions for thousands of years, but after promising uses in the 1950’s and 1960’s they were largely prohibited in medical treatment and human research starting in the 1970’s as part of the fallout from the war on drugs. Nonetheless, there are a number of studies which suggest that these substances have potential applications in the treatment of addictions. While these substances are generally classified as [...]
Lire la suiteThe Past and Future of Psychedelic Science : An Introduction to This Issue Richard E. Doblin, Merete Christiansen, Lisa Jerome, Brad Burge JOURNAL OF PSYCHOACTIVE DRUGS, 2019, VOL. 51, NO. 2, 93–97 https://doi.org/10.1080/02791072.2019.1606472 ABSTRACT Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of scientific and cultural exploration in the1950s and ‘60s, psychedelic research was [...]
Lire la suiteCan Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect ? Jacob S. Aday, Emily K. Bloesch, & Christopher C. Davoli Journal of Cognitive Enhancement, August 2019 DOI: 10.1007/s41465-019-00151-6 Abstract Older adulthood can be characterized by various cognitive and affective changes. In general, older adults show declines in creativity and executive functioning. They also score lower in openness to experience, empathy, and many suffer from a paucity of meaningful experiences. Further, depression, pessimism, and suicide can be major concerns for this population. Although currently there are few interventions that can effectively address these changes, recent findings from psychedelic science suggest myriad parallels between the effects [...]
Lire la suiteClinicians’ Guide to Cannabidiol and Hemp Oils Harrison J. VanDolah, Brent A. Bauer, and Karen F. Mauck Mayo Clinic Proceedings, 2019, 94, (9), 1840-1851 https://doi.org/10.1016/j.mayocp.2019.01.003 Abstract Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and [...]
Lire la suiteSwitch to mania after ayahuasca consumption in a man with bipolar disorder : a case report Alejandro G Szmulewicz, Marina P Valerio and Jose M Smith International Journal of Bipolar Disorders, 2015, 3, (4), 1-3. DOI 10.1186/s40345-014-0020-y Abstract Background : There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing evidence for the antidepressant properties of its components. However, there are no reports on the effects of this substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor. Case report : We present the case of [...]
Lire la suite2018 : A Watershed Year for Psychedelic Science ? Jacob S. Aday, Christopher C. Davoli, & Emily K. Bloesch Article, ·August 2019 DOI: 10.1177/2050324519872284 Abstract While interest in the study of psychedelic drugs has increased over much of the last decade, in this article we argue that 2018 marked the true turning point for the field. Substantive advances in the scientific, public, and regulatory communities in 2018 significantly elevated the status and long-term outlook of psychedelic science, particularly in the United States. Advances in the scientific community can be attributed to impactful research applications of psychedelics as well as acknowledgement in preeminent journals. In the [...]
Lire la suiteSALVIA DIVINORUM AND SALVINORIN A The Best of The Entheogen Review David Aardvark, Editor ER MONOGRAPH SERIES, NO. 2, 1992–2000, Second Edition The Entheogen Review POB 19820 Sacramento, CA 95819-0820 TABLE OF CONTENTS A NOTE ON THE TEXT 9 CHAPTER ONE : The Early Years 11 CHAPTER TWO : Consumption Methods 21 CHAPTER THREE : Hyperspatial Maps 45 CHAPTER FOUR : Extraction 73 CHAPTER FIVE : Salvinorin A & More 81 CHAPTER SIX : Combinations 103 CHAPTER SEVEN : Cultivation 113 CHAPTER EIGHT : Reviews, Interviews, Commentary & Press 133 APPENDIX A : Sources 171 APPENDIX B : The Internet 185 ANNOTATED BIBLIOGRAPHY 197 INDEX 231 ACKNOWLEDGMENTS 249 A NOTE ON THE TEXT Most of the information presented herein comes from the first [...]
Lire la suite